PC14586 (revetrectinib)
Advanced solid tumors with p53 Y220C mutation
Key Facts
Indication
Advanced solid tumors with p53 Y220C mutation
Phase
Phase 1/2
Status
Active
Company
About PMV Pharmaceuticals
PMV Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, small molecule therapies that selectively target p53 mutations, which are among the most common genetic drivers of cancer. The company's lead program, PC14586, is a first-in-class p53 Y220C reactivator currently in Phase 1/2 clinical trials. PMV's strategy centers on creating tumor-agnostic treatments that address specific p53 mutations, aiming to transform cancer care by targeting a fundamental oncogenic mechanism across multiple tumor types.
View full company profile